Behind any landmark cure is years of medical research. But the old goal of research \u2014 to find a one-size-fits-all treatment for a disease, based on a set of standard protocols \u2014 must radically change to further and diversify advances in the field, experts argued at the TIME 100 Health Summit on Thursday.<\/p>\n
Sean Parker, an entrepreneur and founder of the Parker Institute for Cancer Immunotherapy, came to the complex world of biotech, life sciences and health care research as an outsider. (Parker co-founded Napster and was the first president of Facebook.) \u201cIt seemed like there was tremendous opportunity. The field looked and felt a lot like the early Internet,\u201d he explained at the summit.<\/p>\n
\u201cThere was a lot of similarity in terms of enthusiasm and excitement and breakthroughs\u2026 and yet there were these inherent systemic obstacles that felt like they were slowing down progress,\u201d Parker said. The cost of enrolling a patient in a clinical trial, for instance, can be \u201cextraordinarily high,\u201d and researchers focused on similar treatment goals often work separately from one another \u2014 without sharing data. The Parker Institute\u2019s goal is to connect cancer doctors, share information among researchers and accelerate new treatments. Work at the Parker Institute<\/a> has led to the first approved gene immunotherapy for blood cancers and Nobel Prize-winning immune-based cancer drugs.<\/p>\n \u201cWe\u2019re all in it, at the end of the day, for our patients,\u201d said Dr. Laura Esserman, professor of surgery at the University of California, San Francisco School of Medicine. \u201cWe want to get people to a better outcome.\u201d In the field of breast cancer, for example, the same cancer screening and treatment guidelines have traditionally been applied across the board. But people have different genetic profiles and risk factors, necessitating a range of different approaches. \u201cBreast cancer is many diseases,\u201d Esserman said, and a treatment path for one patient may not be appropriate for another.<\/p>\n <\/p>\nThe Brief Newsletter<\/h3>\n